Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

GlycoMimetics, Inc. (GLYC)

0.6156   -0.046 (-6.9%) 06-26 22:44
Open: 0.676 Pre. Close: 0.6612
High: 0.676 Low: 0.6156
Volume: 151,955 Market Cap: 32(M)
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.68 - 0.68 0.68 - 0.68
Low: 0.61 - 0.61 0.61 - 0.61
Close: 0.61 - 0.62 0.62 - 0.62

Technical analysis

as of: 2022-06-24 4:40:19 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.76     One year: 0.86
Support: Support1: 0.5    Support2: 0.42
Resistance: Resistance1: 0.65    Resistance2: 0.74
Pivot: 0.62
Moving Average: MA(5): 0.63     MA(20): 0.63
MA(100): 0.89     MA(250): 1.47
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 53.8     %D(3): 53.5
RSI: RSI(14): 46.5
52-week: High: 2.5  Low: 0.5
Average Vol(K): 3-Month: 189 (K)  10-Days: 222 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GLYC ] has closed above bottom band by 45.4%. Bollinger Bands are 44.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Sat, 18 Jun 2022
Stock Analysts' New Coverage for June 18th (AAMC, AAU, ABIO, AHPI, BIOL, CERN, FB, GALT, GLYC, JOB) - Defense World

Sat, 18 Jun 2022
GlycoMimetics (NASDAQ:GLYC) Now Covered by - Defense World

Fri, 10 Jun 2022
GlycoMimetics (NASDAQ:GLYC) Earns Hold Rating from Analysts at - Defense World

Sat, 04 Jun 2022
GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely - Simply Wall St

Fri, 03 Jun 2022
A GlycoMimetics, Inc. (NASDAQ:GLYC) insider increased their holdings last year - Yahoo Eurosport UK

Thu, 02 Jun 2022
GlycoMimetics to Participate at Upcoming Jefferies 2022 Healthcare Conference - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 52 (M)
% Held by Insiders 3.263e+007 (%)
% Held by Institutions 1.9 (%)
Shares Short 605 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -6.357e+007
EPS Est Next Qtl -0.29
EPS Est This Year -1.22
EPS Est Next Year -0.94
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -61
Return on Assets (ttm) 180.7
Return on Equity (ttm) -36.4
Qtrly Rev. Growth 104330
Gross Profit (p.s.) 0
Sales Per Share -34.24
EBITDA (p.s.) 601036
Qtrly Earnings Growth -1.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -57 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 0.91

Stock Dividends

Dividend 0
Forward Dividend 613660
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.